Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients

Journal of Proteome Research

Volumn 12, Issue 3, 2013, Pages 1101-1107

  Stoop, Marcel P ^a   Singh, Vaibhav ^a   Stingl, Christoph ^a   Martin, Roland ^b,c   Khademi, Mohsen ^d   Olsson, Tomas ^d   Hintzen, Rogier Q ^a   Luider, Theo M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cerebrospinal fluid proteome; natalizumab; selected reaction monitoring

Indexed keywords

BIOLOGICAL MARKER; CHITINASE; CHITINASE 3 LIKE PROTEIN 1; HAPTOGLOBIN; IMMUNOGLOBULIN MU CHAIN; IMMUNOGLOBULIN MU CHAIN C; INFLAMMASOME; NATALIZUMAB; PROTEOME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ELECTROSPRAY MASS SPECTROMETRY; ELECTROSPRAY ORBITRAP MASS SPECTROMETRY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REACTOR MONITORING; SELECTED REACTION MONITORING; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874623590     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr3012107     Document Type: Article

References (26)

1. Oksenberg, J. R.; Baranzini, S. E.; Sawcer, S.; Hauser, S. L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis Nat. Rev. Genet. 2008, 9, 516-26
2. Hauser, S. L.; Oksenberg, J. R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration Neuron 2006, 52, 61-76
3. Bielekova, B.; Martin, R. Development of biomarkers in multiple sclerosis Brain 2004, 127, 1463-78
4. Miller, D. H.; Leary, S. M. Primary-progressive multiple sclerosis Lancet Neurol. 2007, 6, 903-12
5. Compston, A.; Coles, A. Multiple sclerosis Lancet 2008, 372, 1502-17
6. Jacobs, L. D.; Cookfair, D. L.; Rudick, R. A.; Herndon, R. M.; Richert, J. R.; Salazar, A. M.; Fischer, J. S.; Goodkin, D. E.; Granger, C. V.; Simon, J. H.; Alam, J. J.; Bartoszak, D. M.; Bourdette, D. N.; Braiman, J.; Brownscheidle, C. M.; Coats, M. E.; Cohan, S. L.; Dougherty, D. S.; Kinkel, R. P.; Mass, M. K.; Munschauer, F. E., 3rd; Priore, R. L.; Pullicino, P. M.; Scherokman, B. J.; Whitham, R. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann. Neurol. 1996, 39, 285-94
7. Johnson, K. P.; Brooks, B. R.; Cohen, J. A.; Ford, C. C.; Goldstein, J.; Lisak, R. P.; Myers, L. W.; Panitch, H. S.; Rose, J. W.; Schiffer, R. B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 1995, 45, 1268-76
8. Polman, C. H.; O'Connor, P. W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D. H.; Phillips, J. T.; Lublin, F. D.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, M. A.; Sandrock, A. W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 2006, 354, 899-910
9. Yednock, T. A.; Cannon, C.; Fritz, L. C.; Sanchez-Madrid, F.; Steinman, L.; Karin, N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 1992, 356, 63-6
10. Ottervald, J.; Franzen, B.; Nilsson, K.; Andersson, L. I.; Khademi, M.; Eriksson, B.; Kjellstrom, S.; Marko-Varga, G.; Vegvari, A.; Harris, R. A.; Laurell, T.; Miliotis, T.; Matusevicius, D.; Salter, H.; Ferm, M.; Olsson, T. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers J. Proteomics 2010, 73, 1117-32
11. Olsen, J. V.; de Godoy, L. M.; Li, G.; Macek, B.; Mortensen, P.; Pesch, R.; Makarov, A.; Lange, O.; Horning, S.; Mann, M. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap Mol. Cell. Proteomics 2005, 4, 2010-21
12. Comabella, M.; Fernandez, M.; Martin, R.; Rivera-Vallve, S.; Borras, E.; Chiva, C.; Julia, E.; Rovira, A.; Canto, E.; Alvarez-Cermeno, J. C.; Villar, L. M.; Tintore, M.; Montalban, X. Cerebrospinal fluid Chitinase 3-like 1 levels are associated with conversion to multiple sclerosis Brain 2010, 133, 1082-93
13. Stoop, M. P.; Dekker, L. J.; Titulaer, M. K.; Lamers, R. J.; Burgers, P. C.; Sillevis Smitt, P. A.; van Gool, A. J.; Luider, T. M.; Hintzen, R. Q. Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins J. Proteome Res. 2009, 8, 1404-14
14. Stoop, M. P.; Dekker, L. J.; Titulaer, M. K.; Burgers, P. C.; Sillevis Smitt, P. A.; Luider, T. M.; Hintzen, R. Q. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry Proteomics 2008, 8, 1576-85
15. Selewski, D. T.; Shah, G. V.; Segal, B. M.; Rajdev, P. A.; Mukherji, S. K. Natalizumab (Tysabri) AJNR Am. J. Neuroradiol. 2010, 31, 1588-90
16. Ley, K.; Laudanna, C.; Cybulsky, M. I.; Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated Nat. Rev. Immunol. 2007, 7, 678-89
17. Gunnarsson, M.; Malmestrom, C.; Axelsson, M.; Sundstrom, P.; Dahle, C.; Vrethem, M.; Olsson, T.; Piehl, F.; Norgren, N.; Rosengren, L.; Svenningsson, A.; Lycke, J. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab Ann. Neurol. 2011, 69, 83-9
18. Zhang, H. L.; Zhang, X. M.; Mao, X. J.; Deng, H.; Li, H. F.; Press, R.; Fredrikson, S.; Zhu, J. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy Acta Neurol. Scand. 2012, 125, 129-35
19. Villar, L. M.; Masjuan, J.; Gonzalez-Porque, P.; Plaza, J.; Sadaba, M. C.; Roldan, E.; Bootello, A.; Alvarez-Cermeno, J. C. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis Ann. Neurol. 2003, 53, 222-6
20. Sladkova, V.; Mares, J.; Lubenova, B.; Zapletalova, J.; Stejskal, D.; Hlustik, P.; Kanovsky, P. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome Neurol. Res. 2011, 33, 415-20
21. Renkema, G. H.; Boot, R. G.; Au, F. L.; Donker-Koopman, W. E.; Strijland, A.; Muijsers, A. O.; Hrebicek, M.; Aerts, J. M. Chitotriosidase, a Chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages Eur. J. Biochem. 1998, 251, 504-9
22. Jensen, B. V.; Johansen, J. S.; Price, P. A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer Clin. Cancer Res. 2003, 9, 4423-34
23. Kucur, M.; Isman, F. K.; Balci, C.; Onal, B.; Hacibekiroglu, M.; Ozkan, F.; Ozkan, A. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia Urol. Oncol. 2008, 26, 47-52
24. Vos, K.; Steenbakkers, P.; Miltenburg, A. M.; Bos, E.; van Den Heuvel, M. W.; van Hogezand, R. A.; de Vries, R. R.; Breedveld, F. C.; Boots, A. M. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions Ann. Rheum. Dis. 2000, 59, 544-8
25. Comabella, M.; Dominguez, C.; Rio, J.; Martin-Gallan, P.; Vilches, A.; Vilarrasa, N.; Espejo, C.; Montalban, X. Plasma chitotriosidase activity in multiple sclerosis Clin. Immunol. 2009, 131, 216-22
26. Sotgiu, S.; Barone, R.; Arru, G.; Fois, M. L.; Pugliatti, M.; Sanna, A.; Rosati, G.; Musumeci, S. Intrathecal chitotriosidase and the outcome of multiple sclerosis Mult. Scler. 2006, 12, 551-7